Press releases | WebDisclosure

Basculer en Français

11276	Companies
250581	Keywords
179219	Articles
136421	Press releases

Home
Press releases

PRESS RELEASE

published on 05/28/2024 at 07:30, 2 years 5 months ago

EUROPLASMA: FIN DES OPÉRATIONS DE REGROUPEMENT DES ACTIONS ET PREMIÈRE COTATION DES ACTIONS NOUVELLES
Europlasma finalise les opérations de regroupement d'actions et obtient sa première cotation pour les actions nouvelles sur Euronext Growth Paris. Les actionnaires concernés doivent se référer aux informations communiquées

Euronext Growth Paris Actionnaires Europlasma Cotation Regroupement D'actions
PRESS RELEASE

published on 05/28/2024 at 07:30, 2 years 5 months ago

Adler Group S.A. with continued solid operational performance in Q1 2024
Adler Group S.A. reports solid operational performance in Q1 2024 with net rental income of €51m, like-for-like rental growth, and disposals of development projects

Adler Group S.A. Operational Performance Q1 2024 Net Rental Income Portfolio Disposals
PRESS RELEASE

published on 05/28/2024 at 07:30, 2 years 5 months ago

BRAIN Biotech AG receives major milestone payment and stays on-track to achieve year end targets
BRAIN Biotech AG receives significant milestone payment of € 1.5 million and maintains progress towards year-end goals with strengthened cash position. Half-year results show revenue growth and improved EBITDA

Financial Results EBITDA Revenue Growth BRAIN Biotech AG Milestone Payment
PRESS RELEASE

published on 05/28/2024 at 07:30, 2 years 5 months ago

Evotec and CHDI Foundation extend strategic drug discovery collaboration in Huntington’s disease
Evotec SE extends strategic drug discovery collaboration with CHDI Foundation in Huntington's disease, emphasizing commitment to developing new therapies and improving patients' lives

Drug Discovery Evotec SE Therapeutics CHDI Foundation Huntington's Disease
PRESS RELEASE

published on 05/28/2024 at 07:30, 2 years 5 months ago

Inside Information / Other news releases
Sensorion announces its participation in upcoming investor conferences in June 2024 to present its novel therapies for hearing loss disorders. The company will attend conferences in New York, Miami, and Lyon

Biotechnology Investor Conferences June 2024 Sensorion Hearing Loss Disorders
PRESS RELEASE

published on 05/28/2024 at 07:30, 2 years 5 months ago

Informations privilégiées / Autres communiqués
Sensorion annonce sa participation à des conférences investisseurs en juin 2024. Inscrivez-vous aux événements clés de l'entreprise de biotechnologie spécialisée dans les thérapies de perte auditive

Biotechnologie Conférences Investisseurs Événements Sensorion Thérapies Auditives
PRESS RELEASE

published on 05/28/2024 at 07:00, 2 years 5 months ago

LEM with solid performance for full year 2023/24 in weakening markets
LEM announces solid performance for full year 2023/24 despite weakening markets. Sales maintained, EMEA and Rest of Asia grow, China decline. EBIT margin at 20.0%. Dividend proposed at CHF 50 per share

Dividend Proposal Full Year Results EMEA Sales Performance LEM
PRESS RELEASE

published on 05/28/2024 at 07:00, 2 years 5 months ago

Branicks Group launches first fund in new renewables asset class
Branicks Group AG launches first fund in new renewables asset class, targeting 8% p.a. returns and EUR 300 million volume

Branicks Group AG ESG Renewables Return On Investment Fund Launch
PRESS RELEASE

published on 05/28/2024 at 07:00, 2 years 5 months ago

Sunrise Medical plans listing on the Frankfurt Stock Exchange
Sunrise Medical announces IPO plan to list on Frankfurt Stock Exchange, strengthening growth potential and financial profile in the complex rehabilitation market

Financial Performance Frankfurt Stock Exchange IPO Sunrise Medical Rehabilitation Market
PRESS RELEASE

published on 05/28/2024 at 07:00, 2 years 5 months ago

Informations privilégiées / Autres communiqués
Innate Pharma annonce sa participation à des conférences investisseurs mondiales à venir. Détails des conférences et objectif de la société biotechnologique axée sur les immunothérapies contre le cancer

Biotechnologie Immunothérapie Cancer Conférences Investisseurs Innate Pharma

Accesswire

Published on 11/04/2026 at 23:10, 3 hours 53 minutes ago

Ur-Energy Announces Date for Third Quarter 2026 Results and Conference Call and Webcast
Published on 11/04/2026 at 23:00, 4 hours 3 minutes ago

Avino Reports Q3 2026 Financial Results
Published on 11/04/2026 at 23:00, 4 hours 3 minutes ago

Viemed Healthcare Announces Third Quarter 2026 Financial Results
Published on 11/04/2026 at 22:15, 4 hours 48 minutes ago

Zomedica Announces Record Third Quarter Revenue of $9.9 Million, Up 22% Year-Over-Year, Net Loss Reduced 48%, with $41 Million in Liquidity
Published on 11/04/2026 at 22:05, 4 hours 58 minutes ago

Stabilis Solutions Announces Third Quarter 2026 Results

View all ACCESSWIRE

EQS Group

Published on 11/05/2026 at 00:02, 3 hours 1 minute ago

EQS-Adhoc: NEXTDC Limited: Response to Share Raid by Goodman Group and Digital Realty
Published on 11/04/2026 at 19:41, 7 hours 22 minutes ago

EQS-Adhoc: SNP SE Raises Outlook for the Full Year 2026
Published on 11/04/2026 at 19:25, 7 hours 38 minutes ago

Menarini Group and Ryvu Therapeutics Announce First Clinical Data from the Phase II JASPIS-01 Study of dapolsertib (MEN1703, SEL24) in Heavily Pretreated Relapsed/Refractory Aggressive B-cell non-Hodgkin Lymphoma at the 2026 ASH Annual Meeting
Published on 11/04/2026 at 18:43, 8 hours 20 minutes ago

EQS-Adhoc: Deutsche EuroShop refines its revenue forecast and raises its earnings forecast for the 2026 financial year
Published on 11/04/2026 at 18:05, 8 hours 58 minutes ago

Redis Expands Redis Iris to Give AI Agents the Memory, Context, and Messaging They Need to get to Production

Les Echos

Published on 11/04/2026 at 18:00, 9 hours 3 minutes ago

The Belgian State and Engie Group have agreed to extend the target date for concluding the Heads of Terms until 12 December 2026
Published on 11/04/2026 at 18:00, 9 hours 3 minutes ago

L’État belge et le groupe ENGIE ont convenu de se donner un délai supplémentaire jusqu’au 12 décembre 2026 pour la conclusion des Heads of Terms
Published on 11/04/2026 at 17:45, 9 hours 18 minutes ago

October 2026
Published on 11/04/2026 at 17:45, 9 hours 18 minutes ago

Octobre 2026
Published on 11/04/2026 at 17:44, 9 hours 19 minutes ago

Aéroports de Paris SA - Information regarding the voting rights and shares as of 31 October 2026

View all LES ECHOS COMFI WIRE